This study concluded that the market for 5α-reductase inhibitors, including finasteride, epristeride, and dutasteride, is expected to grow with promising prospects.
3 citations
,
September 2024 in “Frontiers in Bioscience-Scholar”
This study reported that Pantaneiro sheep from the Pantanal region of Brazil exhibit greater genetic variability and adaptability compared to the commercial Texel breed, highlighting their potential for further research and importance in Brazilian sheep farming.
This study found that serum bone metabolic markers with mild changes are interdependently related to traditional Chinese medicine syndromes in patients with chronic kidney disease-related bone disorders.
22 citations
,
January 2019 in “Hormone and Metabolic Research”
This meta-analysis confirmed associations between some androgenic and metabolic parameters in women with PCOS, suggesting that these measurements might help predict metabolic risk in this population.
This article discusses the broad traditional uses and potential pharmaceutical applications of burdock, recommending the development of new products but reporting no experimental findings.
The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
RU58841 can be absorbed systemically after topical application, but the study did not find immediate hormonal disruption. The study highlights the need for more research on long-term safety and effects of RU58841, as well as the importance of quality control in products from the grey market.
PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.